MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 11 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Utility of adjuvant systemic therapy in melanoma
A.M.M. Eggermont, Alessandro Testori, J.R. Marsden, Peter Hersey, Ian Quirt, Teresa M. Petrella +3 more
2009· review· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
46
citations
affno abstractunlabeled
Severe novel influenza A (H1N1) infection in cancer patients
Ludhmila Abrahão Hajjar, Thaís Mauad, Filomena Regina Barbosa Gomes Galas, Luiz Fernando Ferraz da Silva, Marisa Dolhnikoff, Thalia Rodrigues Trielli +8 more
2010· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
43
citations
affaboutno abstractunlabeled
LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
D. J. Renouf, Jennifer J. Knox, Petr Kavan, Derek J. Jonker, Stephen Welch, Félix Couture +14 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
40
citations
affno abstractunlabeled
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
Pascal Piedbois, D. Serin, Franck Priou, P. Laplaige, S. Greget, Élisabeth Angellier +7 more
2006· article· en· Annals of Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
40
citations
fundno affno abstractgemma · no categorygpt · no categorymodels agree
LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Isabelle Laure Ray-Coquard, Alexandra Léary, Sandro Pignata, Claire Cropet, Andrew Martin, Gerhard Bogner +14 more
2022· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
40
citations

How this was built: Screen · Findings · About